January 30, 2022
1 min read
Save
Nevro receives FDA expanded labeling approval for spinal cord stimulation system
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Nevro Corp. has announced FDA approval for expanded labeling of its Senza spinal cord stimulation system for use in patients with non-surgical refractory back pain, according to a press release.
The Senza system utilizes 10kHZ spinal cord stimulation therapy to provide pain relief in patients, according to the release.
“Patients who suffer from intractable back pain without a prior surgery have limited treatment options if they are not a candidate for surgery,” D. Keith Grossman, chair, CEO and president of Nevro, said in the release. “This FDA approval marks another milestone in Nevro's commitment to expanding access to 10kHz therapy for these underserved patients.”
Published by:
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.